Home › Compare › TFFP vs QYLD

TFFP vs QYLD: Dividend Comparison 2026

TFFP yields 3076.92% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TFFP wins by $578804600665.47M in total portfolio value
10 years
TFFP
TFFP
● Live price
3076.92%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$578804600665.50M
Annual income
$544,023,840,488,516,100.00
Full TFFP calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — TFFP vs QYLD

📍 TFFP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTFFPQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TFFP + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TFFP pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TFFP
Annual income on $10K today (after 15% tax)
$261,538.46/yr
After 10yr DRIP, annual income (after tax)
$462,420,264,415,238,660.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, TFFP beats the other by $462,420,264,415,233,860.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TFFP + QYLD for your $10,000?

TFFP: 50%QYLD: 50%
100% QYLD50/50100% TFFP
Portfolio after 10yr
$289402300332.76M
Annual income
$272,011,920,244,260,860.00/yr
Blended yield
93.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on TFFP right now

TFFP
Analyst Ratings
5
Buy
Consensus: Buy
Altman Z
-34.6
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TFFP buys
0
QYLD buys
0
No recent congressional trades found for TFFP or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTFFPQYLD
Forward yield3076.92% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$578804600665.50M ✓$25.4K
Annual income after 10y$544,023,840,488,516,100.00 ✓$5,659.31
Total dividends collected$576403114825.48M ✓$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TFFP vs QYLD ($10,000, DRIP)

YearTFFP PortfolioTFFP Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$318,392$307,692.31$10,352$1,192.36+$308.0K → TFFP
2$9,496,461$9,155,781.67$10,830$1,347.57+$9.49M → TFFP
3$265,378,974$255,217,760.17$11,460$1,539.07+$265.37M → TFFP
4$6,949,441,440$6,665,485,937.77$12,275$1,777.84+$6949.43M → TFFP
5$170,564,997,752$163,129,095,411.51$13,323$2,078.95+$170564.98M → TFFP
6$3,924,365,658,393$3,741,861,110,798.54$14,667$2,463.34+$3924365.64M → TFFP
7$84,659,703,250,880$80,460,631,996,399.20$16,396$2,960.57+$84659703.23M → TFFP
8$1,712,795,370,094,185$1,622,209,487,615,743.00$18,631$3,612.97+$1712795370.08M → TFFP
9$32,505,383,342,974,930$30,672,692,296,974,148.00$21,548$4,482.15+$32505383342.95M → TFFP
10$578,804,600,665,499,400$544,023,840,488,516,100.00$25,398$5,659.31+$578804600665.47M → TFFP

TFFP vs QYLD: Complete Analysis 2026

TFFP — Stock

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

Full TFFP Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this TFFP vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TFFP vs SCHDTFFP vs JEPITFFP vs OTFFP vs KOTFFP vs MAINTFFP vs XYLDTFFP vs JEPQTFFP vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.